Program Year 2022
General Payments867,517 providers 1,753 companies
Dataset totals — PY2022
$2,729,211,156.11
- Category: General Payments
- Program year: 2022
- Records: 13,267,544
- Providers: 867,517
- Reporting companies: 1,753
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- Dataset-level totals for the labeled program year, General Payments only. Research and Ownership/Investment are separate datasets and are never combined into these figures.
- Methodology & Data — sourcing, labeling, and limitations.
Coverage: program years 2018–2024 are loaded, General Payments only. This page reflects the CMS publication snapshot for PY2022.
Reported totals by company — PY2022 (20 shown)
Sorted by reported total — a dataset fact, not a ranking of conduct.
| Company | Reported | Records | Providers |
|---|---|---|---|
| PFIZER INC. | $264,780,089.66 | 286,200 | 102,328 |
| ABBVIE INC. | $137,880,121.46 | 1,545,929 | 206,762 |
| DePuy Synthes Products LLC | $125,430,724.98 | 2,381 | 475 |
| Medtronic, Inc. | $121,140,692.84 | 307,076 | 69,706 |
| Stryker Corporation | $106,920,295.89 | 137,980 | 28,695 |
| Arthrex, Inc. | $94,202,206.78 | 43,297 | 3,737 |
| Smith & Nephew, Inc. | $72,009,864.03 | 71,115 | 21,410 |
| Zimmer Biomet Holdings, Inc. | $62,775,788.65 | 31,189 | 8,163 |
| BOSTON SCIENTIFIC CORPORATION | $56,471,151.91 | 204,002 | 58,188 |
| INTUITIVE SURGICAL, INC. | $53,884,904.71 | 94,192 | 14,119 |
| Allergan Inc. | $51,201,079.96 | 135,545 | 33,051 |
| Acerta Pharma LLC | $40,367,276.25 | 433,682 | 109,959 |
| TRIAD LIFE SCIENCES INC. | $35,350,078.09 | 2,654 | 1,240 |
| Novo Nordisk AS | $33,932,718.68 | 522,286 | 92,206 |
| Lilly USA, LLC | $33,920,002.38 | 401,253 | 94,782 |
| Abbott Laboratories | $31,468,287.99 | 311,204 | 69,748 |
| GlaxoSmithKline, LLC. | $28,527,756.48 | 338,564 | 83,071 |
| E.R. Squibb & Sons, L.L.C. | $27,869,055.13 | 158,487 | 55,162 |
| Amgen Inc. | $24,032,726.87 | 403,103 | 99,638 |
| Janssen Pharmaceuticals, Inc | $22,599,999.10 | 292,193 | 82,779 |
Reported totals by specialty — PY2022 (20 shown)
Sorted by reported total.
Other program years
Natures of payment
- Royalty or License
- Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
- Consulting Fee
- Food and Beverage
- Acquisitions
- Travel and Lodging
- Education
- Honoraria
- Current or prospective ownership or investment interest
- Grant
- Compensation for serving as faculty or as a speaker for a medical education program
- Gift
- Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program
- Debt forgiveness
- Long term medical supply or device loan
- Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program
- Charitable Contribution
- Entertainment